Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and raises the price target from $20 to $22.